HYDROXYFASUDIL MONOHYDROCHLORIDE manufacturers
|
| | HYDROXYFASUDIL MONOHYDROCHLORIDE Basic information |
| | HYDROXYFASUDIL MONOHYDROCHLORIDE Chemical Properties |
| Melting point | >250 (dec.) | | storage temp. | Inert atmosphere,2-8°C | | solubility | H2O: >5mg/mL | | form | solid | | color | white | | Water Solubility | Soluble in water (20mM) | | InChI | InChI=1S/C14H17N3O3S.ClH/c18-14-12-3-1-4-13(11(12)5-7-16-14)21(19,20)17-9-2-6-15-8-10-17;/h1,3-5,7,15H,2,6,8-10H2,(H,16,18);1H | | InChIKey | XWWFOUVDVJGNNG-UHFFFAOYSA-N | | SMILES | c1c(S(=O)(=O)N2CCNCCC2)c2ccnc(O)c2cc1.Cl |
| Hazard Codes | Xn | | Risk Statements | 22 | | WGK Germany | 3 | | Storage Class | 11 - Combustible Solids | | Hazard Classifications | Acute Tox. 4 Oral |
| | HYDROXYFASUDIL MONOHYDROCHLORIDE Usage And Synthesis |
| Chemical Properties | Off-White Solid | | Uses | A metabolite of Fasudil. A cell-permeable, hydroxylated metabolite of HA 1077 that displays anti-anginal properties. Reported to inhibit the Rho kinase-mediated (ROCK) contraction both in vitro and in vivo. | | General Description | A cell-permeable, hydroxylated metabolite of HA 1077 (Fasudil; Cat. No. 371970) that displays anti-anginal properties. Acts as an ATP-competitive and a reversible inhibitor of Rho-kinase (IC50 = 0.9 and 1.8 μM using a peptide and MLC as substrate, respectively) with ~100-fold greater selectivity over MLCK, MRCKβ, and PKC. Reported to inhibit the Rho kinase-mediated contraction both in vitro and in vivo. | | Biochem/physiol Actions | Cell permeable: yes | | storage | -20°C |
| | HYDROXYFASUDIL MONOHYDROCHLORIDE Preparation Products And Raw materials |
|